Kuchyne na miru

Pharmaceutical Executive August 2018

August 2018 | Volume 38, Issue 8
Pharmaceutical Executive August 2018
From the Editor
A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive August 2018 issue in an interactive PDF format.
Lisa Henderson examines the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.
Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing, writes Lisa Henderson.
New trends report spotlights the promise and cautions for prospective life sciences dealmakers.
New York City is emerging as a hotspot for biotech incubators, including one startup whose CEO made the leap from big pharma to forging new discoveries in medical science. Michelle Maskaly reports.
Commercial leaders can boost product launches with a data-driven roadmap, writes Erik Cruz.
Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.
Recent bipartisan efforts look to expand access for addiction treatment and stem inappropriate drug prescribing.
Using AI to revolutionize research inefficiency. 
European drug innovators ready their defense as the Commission mulls manufacturing waiver for generic competitors.
Special Sponsored Section
Behind an economic revival in Portugal, including healthcare spending growth, the nation’s life sciences sector is benefiting as well, with Portugal diverging from the European averages to show an increase in R&D and innovation.


lorem ipsum